OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
0126Z0$488000.0059

Samsung Epis Holdings Co Ltd

Biotechnology & Medical ResearchVerified

Samsung Epis Holdings Co Ltd has a market price of 488,000 KRW, with a market capitalization of 12.14 trillion KRW. The company's price-to-book ratio is 2.1, and its price-to-tangible-book ratio is also 2.1, indicating a relatively high valuation compared to its book value. The enterprise value to EBITDA ratio is -180.80, which is significantly negative, reflecting the company's current operating losses. The enterprise value to revenue ratio is 49.23, suggesting a high valuation relative to its revenue. The company's profitability metrics are concerning. The return on equity is -0.54%, and the return on assets is -0.41%, both indicating a negative return on invested capital. The gross profit margin is 36.64%, but the operating margin is -27.23%, and the net margin is -12.47%, all of which are below the industry median for profitability metrics. The debt-to-equity ratio is 0.07, which is relatively low, but the company's current ratio is 1.36, indicating a moderate level of liquidity. Samsung Epis Holdings Co Ltd's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no geographic diversification provided in the available data, suggesting that the company's revenue is primarily derived from a single region. This lack of diversification could pose a concentration risk if the company's primary market experiences economic downturns or regulatory changes. The company's growth trajectory is mixed. The current fiscal year is expected to show a decline in revenue, with a negative outlook for the next fiscal year as well. The operating cash flow is negative at -103.74 billion KRW, and the free cash flow is also negative at -3.26 billion KRW. The capital expenditure is -39.99 billion KRW, indicating significant investment in the business. However, the company's net income is negative at -31.38 billion KRW, and the operating income is also negative at -68.53 billion KRW. The risk assessment for Samsung Epis Holdings Co Ltd indicates a medium level of liquidity risk and a low level of dilution risk. The company's key financial flags include a negative net cash position after subtracting total debt, which could impact its ability to meet short-term obligations. The dilution potential is low, and there are no significant adjustments applied to the valuation metrics. Recent events and disclosures include analyst estimates with a mean price target of 695,000 KRW and a median price target of 695,000 KRW. The mean recommendation is 2.33, indicating a hold rating. There are two buy recommendations and one hold recommendation, with no strong buy or strong sell ratings. These analyst estimates suggest a cautious outlook for the company's stock.

30-day price · 0126Z0(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanySamsung Epis Holdings Co Ltd
Ticker0126Z0.KS
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Samsung Epis Holdings Co Ltd operates in the Biotechnology & Medical Research industry, focusing on Pharmaceuticals & Medical Research.

Classification. The company is classified under the Healthcare economic sector, with a high confidence level of 0.92 in its placement within the Biotechnology & Medical Research industry.

Samsung Epis Holdings Co Ltd has a market price of 488,000 KRW, with a market capitalization of 12.14 trillion KRW. The company's price-to-book ratio is 2.1, and its price-to-tangible-book ratio is also 2.1, indicating a relatively high valuation compared to its book value. The enterprise value to EBITDA ratio is -180.80, which is significantly negative, reflecting the company's current operating losses. The enterprise value to revenue ratio is 49.23, suggesting a high valuation relative to its revenue. The company's profitability metrics are concerning. The return on equity is -0.54%, and the return on assets is -0.41%, both indicating a negative return on invested capital. The gross profit margin is 36.64%, but the operating margin is -27.23%, and the net margin is -12.47%, all of which are below the industry median for profitability metrics. The debt-to-equity ratio is 0.07, which is relatively low, but the company's current ratio is 1.36, indicating a moderate level of liquidity. Samsung Epis Holdings Co Ltd's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no geographic diversification provided in the available data, suggesting that the company's revenue is primarily derived from a single region. This lack of diversification could pose a concentration risk if the company's primary market experiences economic downturns or regulatory changes. The company's growth trajectory is mixed. The current fiscal year is expected to show a decline in revenue, with a negative outlook for the next fiscal year as well. The operating cash flow is negative at -103.74 billion KRW, and the free cash flow is also negative at -3.26 billion KRW. The capital expenditure is -39.99 billion KRW, indicating significant investment in the business. However, the company's net income is negative at -31.38 billion KRW, and the operating income is also negative at -68.53 billion KRW. The risk assessment for Samsung Epis Holdings Co Ltd indicates a medium level of liquidity risk and a low level of dilution risk. The company's key financial flags include a negative net cash position after subtracting total debt, which could impact its ability to meet short-term obligations. The dilution potential is low, and there are no significant adjustments applied to the valuation metrics. Recent events and disclosures include analyst estimates with a mean price target of 695,000 KRW and a median price target of 695,000 KRW. The mean recommendation is 2.33, indicating a hold rating. There are two buy recommendations and one hold recommendation, with no strong buy or strong sell ratings. These analyst estimates suggest a cautious outlook for the company's stock.
Key takeaways
  • Samsung Epis Holdings Co Ltd has a high price-to-book ratio of 2.1, indicating a premium valuation relative to its book value.
  • The company's profitability metrics, including a negative return on equity and return on assets, suggest poor financial performance.
  • The company's revenue is concentrated in a single business segment, posing a concentration risk.
  • Analyst estimates suggest a cautious outlook, with a mean price target of 695,000 KRW and a hold recommendation.
  • The company's liquidity position is moderate, with a current ratio of 1.36, but its net cash position is negative after subtracting total debt.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$251.69B
Gross profit$92.23B
Operating income-$68.53B
Net income-$31.38B
R&D
SG&A
D&A
SBC
Operating cash flow-$103.74B
CapEx-$39.99B
Free cash flow-$3.26B
Total assets$7.72T
Total liabilities$1.93T
Total equity$5.79T
Cash & equivalents$131.30B
Long-term debt$378.10B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$251.69B-$68.53B-$31.38B-$3.26B
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$7.72T$5.79T$131.30B
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0-$103.74B-$39.99B-$3.26B
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$488000.00
Market cap$12.14T
Enterprise value$12.39T
P/E
Reported non-GAAP P/E
EV/Revenue49.2
EV/Op income
EV/OCF
P/B2.1
P/Tangible book2.1
Tangible book$5.79T
Net cash-$246.80B
Current ratio1.4
Debt/Equity0.1
ROA-0.4%
ROE-0.5%
Cash conversion3.3%
CapEx/Revenue-15.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
Metric0126Z0Activity
Op margin-27.2%-2.9% medp25 -218.9% · p75 9.6%below median
Net margin-12.5%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin36.6%47.8% medp25 27.6% · p75 68.9%below median
CapEx / revenue-15.9%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity7.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Observations
IR observations
Mean price target695,000.00 KRW
Median price target695,000.00 KRW
High price target770,000.00 KRW
Low price target620,000.00 KRW
Mean recommendation2.33 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count2.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate12,879.07 KRW
Last actual EPS-1,263.00 KRW
Source: analysis-pipeline (hybrid)Generated: 2026-05-18 01:41 UTCJob: 36ab64bb